BindingDB logo
myBDB logout

31 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
25555732 52 Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.EBI Xenon Pharmaceuticals Inc.
24405703 72 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.EBI Janssen Research and Development, LLC
24374272 48 Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.EBI Xenon Pharmaceuticals Inc.
24370012 47 Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.EBI Xenon Pharmaceuticals Inc.
24153205 21 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.EBI Janssen Research and Development, LLC
23395660 48 Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.EBI Sanofi-Aventis Deutschland GmbH
23265904 54 Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).EBI Merck Research Laboratories
23245208 91 Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.EBI Xenon Pharmaceuticals, Inc.
21661758 39 Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.EBI Merck Frosst Centre for Therapeutic Research
17530838 50 Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.EBI Abbott Laboratories
22101133 26 Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.EBI Merck Frosst Centre for Therapeutic Research
22047692 50 Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.EBI Merck Frosst Centre for Therapeutic Research
22209206 35 Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.EBI Merck Frosst Centre for Therapeutic Research
21924609 28 Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.EBI Merck Frosst Centre for Therapeutic Research
21871798 39 Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.EBI Merck Frosst Centre for Therapeutic Research
21356569 20 Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.EBI Daiichi Sankyo Co., Ltd.
21324691 24 N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.EBI Pfizer Inc.
20801551 34 Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.EBI Daiichi Sankyo Co., Ltd.
20933412 83 2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.EBI Merck Frosst Centre for Therapeutic Research
20137926 43 SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.EBI Merck Frosst Centre for Therapeutic Research
20006498 67 Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].EBI Daiichi Sankyo Co. Ltd
20004097 36 Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).EBI Merck Frosst Centre for Therapeutic Research
19926281 56 Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.EBI Daiichi Sankyo Co. Ltd
19632834 16 Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.EBI Merck Frosst Centre for Therapeutic Research
19577469 30 Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.EBI Gilead Sciences, Inc.
19540759 61 Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.EBI Daiichi Sankyo Co., Ltd
19541482 37 Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.EBI Daiichi Sankyo Co., Ltd
19394219 40 Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.EBI CV Therapeutics, Inc
18632269 18 Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.EBI Abbott Laboratories